Clinical Trial

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 23, 2023 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus immunotherapy with concurrent chemoradiotherapy (CCRT) or RT alone in patients with stage III-IVa nasopharyngeal carcinoma(NPC), in order to confirm the value of Immunotherapy and concurrent chemotherapy in NPC patients.
Trial Details
NCT Number NCT06095167
Lead Sponsor Fujian Cancer Hospital
Conditions Nasopharyngeal Carcinoma
Enrollment 476 participants
Start Date 2024-01-01
Primary Completion 2025-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-23